Sensex Bounces Back, Nifty Reclaims 24,000 – Four Factors Behind the Market’s Recovery

The Indian equity market finally breathed a sigh of relief on Friday. By mid‑morning the BSE Sensex, which had been down more than 560 points earlier, was up roughly 200 points from its low, while the NSE Nifty managed to slip back above the psychologically important 24,000 mark.

At 11:37 am IST the Sensex stood at 76,909.17, down 560.94 points (‑0.72 %). The Nifty was at 24,040.30, off 147.40 points (‑0.61 %). In total, 1,301 stocks were in the green, 2,290 fell and 163 were unchanged – a fairly typical breadth for a market that’s just turned the corner after a multi‑day slump.

Four reasons are being cited for the modest bounce.

First, investors seem to be reverting to a classic value‑buying mindset. After three consecutive days of declines, many fund managers and retail participants started picking the cheaper, dividend‑paying names, giving the index a modest lift.

Second, the pharma sector’s drama eased a little. Earlier in the session, news broke that U.S. President Donald Trump was planning a phased tariff on imported generic medicines, with a two‑year grace period. The initial reaction was a sharp 2 % drop for pharma stocks, but as details emerged – and the exact scope of the tariff remained fuzzy – the sell‑off softened to about 1.2 %.

Third, auto makers added some sparkle. Bajaj Auto surged 3.4 % and TVS Motor climbed 4 % after they posted quarterly profits that beat expectations. While analysts warned that global headwinds – such as Middle‑East tensions and high crude prices – still loom, the earnings surprise gave a short‑term lift to the broader market.

Finally, technical traders keep reminding everyone that a decisive break below 24,000 could open the floodgates for further downside. In other words, as long as the Nifty holds above that level, the bearish momentum may stay limited.

On the flow side, foreign institutional investors (FIIs) sold about Rs 819 crore worth of shares, while domestic institutional investors (DIIs) were net sellers of Rs 418 crore. In unrelated news, SEBI granted approval to Carnelian Asset Management to start a mutual‑fund business.

All told, the market’s modest rally looks like a combination of renewed valuation focus, a softening pharma shock, upbeat auto earnings and a key technical support line. Whether the upswing can be sustained will likely hinge on how the tariff story evolves and whether global risk factors ease.